Literature DB >> 10080839

Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine.

A T Eror1, A Stojadinovic, B W Starnes, S C Makrides, G C Tsokos, T Shea-Donohue.   

Abstract

We examined the effect of soluble complement receptor type 1 (sCR1) on mucosal injury and inflammation in a rat model of ischemia/reperfusion. Groups of vehicle- and sCR1-treated rats underwent 30 min of mesenteric ischemia followed by 60 or 120 min of reperfusion. When compared to vehicle-treated rats, treatment with sCR1 (12 mg/kg) prior to 120 min of reperfusion significantly reduced mucosal injury, neutrophil infiltration, leukotriene B4 production, and restored villus height to control levels. The protective effect of sCR1 evident at 120 min of reperfusion was not observed at 60 min of reperfusion despite rapid inactivation of complement. These data suggest that complement inhibition minimized mucosal disruption by facilitating mucosal restitution or interrupting the inflammatory process. Delayed administration of sCR1 for 30 or 60 min into the reperfusion period progressively reduced the protection. sCR1-mediated rapid recovery of rat intestine after ischemia/reperfusion underscores the fundamental role of complement activation in neutrophil-mediated tissue injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080839     DOI: 10.1006/clim.1998.4635

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  18 in total

Review 1.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

2.  Uncoupling protein 2 involved in protection of glucagon-like peptide 2 in small intestine with ischemia-reperfusion injury in mice.

Authors:  Lili Guan; Dezheng Gong; Nan Tian; Yuan Zou
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

3.  Novel multivariate methods for integration of genomics and proteomics data: applications in a kidney transplant rejection study.

Authors:  Oliver P Günther; Heesun Shin; Raymond T Ng; W Robert McMaster; Bruce M McManus; Paul A Keown; Scott J Tebbutt; Kim-Anh Lê Cao
Journal:  OMICS       Date:  2014-11

4.  LPS preconditioning ameliorates intestinal injury in a rat model of hemorrhagic shock.

Authors:  Ruiming Chang; Yingyan Wang; Jianxing Chang; Liqiang Wen; Zhipeng Jiang; Tao Yang; Kai Yu
Journal:  Inflamm Res       Date:  2014-05-20       Impact factor: 4.575

5.  Helicobacter infection alters MyD88 and Trif signalling in response to intestinal ischaemia-reperfusion.

Authors:  Sara M Hoffman; Hua Wang; Michael R Pope; Sherry D Fleming
Journal:  Exp Physiol       Date:  2010-11-05       Impact factor: 2.969

6.  Sca-1 influences the innate immune response during skeletal muscle regeneration.

Authors:  Kimberly K Long; Grace K Pavlath; Monty Montano
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-01       Impact factor: 4.249

7.  TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation.

Authors:  Michael R Pope; Sherry D Fleming
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

Review 8.  Membrane lipid interactions in intestinal ischemia/reperfusion-induced Injury.

Authors:  Emily Archer Slone; Sherry D Fleming
Journal:  Clin Immunol       Date:  2014-05-09       Impact factor: 3.969

9.  Intestinal lipid alterations occur prior to antibody-induced prostaglandin E2 production in a mouse model of ischemia/reperfusion.

Authors:  Byron L Sparkes; Emily E Archer Slone; Mary Roth; Ruth Welti; Sherry D Fleming
Journal:  Biochim Biophys Acta       Date:  2010-01-18

10.  Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury.

Authors:  Liudmila Kulik; Sherry D Fleming; Chantal Moratz; Jason W Reuter; Aleksey Novikov; Kuan Chen; Kathy A Andrews; Adam Markaryan; Richard J Quigg; Gregg J Silverman; George C Tsokos; V Michael Holers
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.